Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/33963 |
Resumo: | Objective: To analyze the advantages and disadvantages of Ozempic for the treatment of obesity. Methods: Through an integrative analysis, it was possible to highlight different investigations in scientific articles. The article established inclusion criteria, such as keywords, publication language and being on one of the preselected platforms (Scielo, PubMed and RDU) and also established exclusion criteria, such as incomplete research, was the subject investigated and without methods and explicit methods. Results: The Ozempic (semaglutide) has good results in helping to lose weight in obese patients. Despite being developed for the treatment of patients with type 2 diabetes mellitus, the results for obesity were positive. Among the main results is weight loss, which is directly conditioned to the dosage of medication, as well as a better energy intake and a lower preference for fatty foods in the patients' choice. All these factors were considered advantages. Among the disadvantages of using the drug is the fact that it is new in the market, which limits scientific research. According to the authors, some researchers have already established a causal relationship between the use of semaglutide and thyroid cancer in rodents; this factor has not been proven in humans and is considered a disadvantage. Final considerations: The use of Ozempic presents interesting results for weight loss, however, although the long-term side effects of the use of this drug are not known, a factor that may pose a risk to patients who are using Ozempic for it. treatment of obesity. |
id |
UNIFEI_da56906b2251b2327c6aab30bebc2ba0 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/33963 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysisOzempic (Semaglutida) para el tratamiento de la obesidad: ventajas y desventajas a partir de un análisis integrativoOzempic (semaglutida) para tratamento da obesidade: vantagens e desvantagens a partir de uma análise integrativaOzempicSemaglutidaObesidadeFarmacologia.OzempicSemaglutidaObesidadFarmacología.OzempicSemaglutideObesityPharmacology.Objective: To analyze the advantages and disadvantages of Ozempic for the treatment of obesity. Methods: Through an integrative analysis, it was possible to highlight different investigations in scientific articles. The article established inclusion criteria, such as keywords, publication language and being on one of the preselected platforms (Scielo, PubMed and RDU) and also established exclusion criteria, such as incomplete research, was the subject investigated and without methods and explicit methods. Results: The Ozempic (semaglutide) has good results in helping to lose weight in obese patients. Despite being developed for the treatment of patients with type 2 diabetes mellitus, the results for obesity were positive. Among the main results is weight loss, which is directly conditioned to the dosage of medication, as well as a better energy intake and a lower preference for fatty foods in the patients' choice. All these factors were considered advantages. Among the disadvantages of using the drug is the fact that it is new in the market, which limits scientific research. According to the authors, some researchers have already established a causal relationship between the use of semaglutide and thyroid cancer in rodents; this factor has not been proven in humans and is considered a disadvantage. Final considerations: The use of Ozempic presents interesting results for weight loss, however, although the long-term side effects of the use of this drug are not known, a factor that may pose a risk to patients who are using Ozempic for it. treatment of obesity.Objetivo: Analizar las ventajas y desventajas de Ozempic para el tratamiento de la obesidad. Métodos: A través de un análisis integrador, fue posible relevar diferentes investigaciones en artículos científicos. El artículo establece criterios de inclusión, como palabras clave, idioma de publicación y estar en una de las plataformas preseleccionadas (Scielo, PubMed y RDU) y también estableció criterios de exclusión, como investigación incompleta, fuera del tema investigado y sin métodos explícitos. Resultados: Ozempic (semaglutida) tiene buenos resultados para ayudar a perder peso. Desarrollado para el tratamiento de pacientes con diabetes mellitus tipo 2, los resultados para la obesidad fueron positivos. Entre los principales resultados está la pérdida de peso, que está directamente condicionada a la dosificación de la medicación, así como una mejor ingesta energética y una menor preferencia por los alimentos grasos en la elección de los pacientes. Todos estos factores se consideraron ventajas. Entre las desventajas de usar el medicamento, está el hecho de que es nuevo en el mercado, lo que limita la investigación científica. Algunos investigadores ya han establecido una relación causal entre el uso de semaglutida y el cáncer de tiroides en roedores (no ha sido probado en humanos) y es desventaja. Consideraciones finales: El uso de Ozempic presenta resultados interesantes para la pérdida de peso, sin embargo, aún no se conocen los efectos secundarios a largo plazo del uso de este medicamento, factor que puede poner en riesgo a los pacientes que están usando Ozempic para el tratamiento de la obesidad.Objetivo: Analisar as vantagens de desvantagens do Ozempic para tratamento da obesidade. Métodos: Através de uma análise integrativa foi possível fazer o levantamento de diferentes pesquisas em artigos científicos. O artigo estabeleceu critérios de inclusão, como palavras chave, língua da publicação e estar em uma das plataformas pré selecionadas (Scielo, PubMed e RDU) e também estabeleceu critérios de exclusão, como pesquisas incompletas, fora da temática pesquisada e sem métodos e resultados explícitos. Resultados: O Ozempic (semaglutida) apresenta bons resultados para auxiliar perda de peso em pacientes obesos. Apesar de ser desenvolvido para tratar pacientes que possuem diabetes mellitus tipo 2, os resultados para obesidade foram positivos. A perda de peso, está diretamente condicionada a dosagem da medicação, assim como melhor ingestão energética e menor preferência por alimentos gordurosos nas escolhas dos pacientes. Todos estes fatores foram considerados vantagens. Dentre as desvantagens da utilização do medicamento, tem-se o fato deste ser novo no mercado, o que limita a pesquisa científica. De acordo com os autores estudados, alguns pesquisadores já estabelecem relação de causalidade entre a utilização da semaglutida e câncer de tireoide em roedores, este fator ainda não foi comprovado em humanos e é considerado como um fator de desvantagem. Considerações Finais: A utilização do Ozempic se apresenta com resultados interessantes para perda de peso, entretanto ainda não se sabe os efeitos colaterais a longo prazo da utilização deste medicamento, fator que pode colocar em risco os pacientes que estão utilizando o Ozempic para tratamento da obesidade.Research, Society and Development2022-09-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3396310.33448/rsd-v11i11.33963Research, Society and Development; Vol. 11 No. 11; e587111133963 Research, Society and Development; Vol. 11 Núm. 11; e587111133963 Research, Society and Development; v. 11 n. 11; e587111133963 2525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/33963/28746Copyright (c) 2022 Hanna Benayon Oliveira Sabbá; Caio Antônio Silva Viana; Caroline Baía Silva; Diogo Ramos Alves; Jhon Lennon Ferreira Miranda; Manuella Carneiro Rodruigues; Pedro Henrique Farias dos Santoshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSabbá, Hanna Benayon OliveiraViana, Caio Antônio SilvaSilva, Caroline BaíaAlves, Diogo RamosMiranda, Jhon Lennon FerreiraRodruigues, Manuella CarneiroSantos, Pedro Henrique Farias dos2022-09-05T13:24:46Zoai:ojs.pkp.sfu.ca:article/33963Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:49:27.038341Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysis Ozempic (Semaglutida) para el tratamiento de la obesidad: ventajas y desventajas a partir de un análisis integrativo Ozempic (semaglutida) para tratamento da obesidade: vantagens e desvantagens a partir de uma análise integrativa |
title |
Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysis |
spellingShingle |
Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysis Sabbá, Hanna Benayon Oliveira Ozempic Semaglutida Obesidade Farmacologia. Ozempic Semaglutida Obesidad Farmacología. Ozempic Semaglutide Obesity Pharmacology. |
title_short |
Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysis |
title_full |
Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysis |
title_fullStr |
Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysis |
title_full_unstemmed |
Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysis |
title_sort |
Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysis |
author |
Sabbá, Hanna Benayon Oliveira |
author_facet |
Sabbá, Hanna Benayon Oliveira Viana, Caio Antônio Silva Silva, Caroline Baía Alves, Diogo Ramos Miranda, Jhon Lennon Ferreira Rodruigues, Manuella Carneiro Santos, Pedro Henrique Farias dos |
author_role |
author |
author2 |
Viana, Caio Antônio Silva Silva, Caroline Baía Alves, Diogo Ramos Miranda, Jhon Lennon Ferreira Rodruigues, Manuella Carneiro Santos, Pedro Henrique Farias dos |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Sabbá, Hanna Benayon Oliveira Viana, Caio Antônio Silva Silva, Caroline Baía Alves, Diogo Ramos Miranda, Jhon Lennon Ferreira Rodruigues, Manuella Carneiro Santos, Pedro Henrique Farias dos |
dc.subject.por.fl_str_mv |
Ozempic Semaglutida Obesidade Farmacologia. Ozempic Semaglutida Obesidad Farmacología. Ozempic Semaglutide Obesity Pharmacology. |
topic |
Ozempic Semaglutida Obesidade Farmacologia. Ozempic Semaglutida Obesidad Farmacología. Ozempic Semaglutide Obesity Pharmacology. |
description |
Objective: To analyze the advantages and disadvantages of Ozempic for the treatment of obesity. Methods: Through an integrative analysis, it was possible to highlight different investigations in scientific articles. The article established inclusion criteria, such as keywords, publication language and being on one of the preselected platforms (Scielo, PubMed and RDU) and also established exclusion criteria, such as incomplete research, was the subject investigated and without methods and explicit methods. Results: The Ozempic (semaglutide) has good results in helping to lose weight in obese patients. Despite being developed for the treatment of patients with type 2 diabetes mellitus, the results for obesity were positive. Among the main results is weight loss, which is directly conditioned to the dosage of medication, as well as a better energy intake and a lower preference for fatty foods in the patients' choice. All these factors were considered advantages. Among the disadvantages of using the drug is the fact that it is new in the market, which limits scientific research. According to the authors, some researchers have already established a causal relationship between the use of semaglutide and thyroid cancer in rodents; this factor has not been proven in humans and is considered a disadvantage. Final considerations: The use of Ozempic presents interesting results for weight loss, however, although the long-term side effects of the use of this drug are not known, a factor that may pose a risk to patients who are using Ozempic for it. treatment of obesity. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-09-04 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/33963 10.33448/rsd-v11i11.33963 |
url |
https://rsdjournal.org/index.php/rsd/article/view/33963 |
identifier_str_mv |
10.33448/rsd-v11i11.33963 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/33963/28746 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 11; e587111133963 Research, Society and Development; Vol. 11 Núm. 11; e587111133963 Research, Society and Development; v. 11 n. 11; e587111133963 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052770862235648 |